Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (271-280 of 293) with videos related to

Pageof 30
Sort By:
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2021
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Katie M Campbell, Ann Marie Egloff, et al.
Cell|July 11, 2025
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanomaEryn Blass, Derin B Keskin, Chloe R Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2020
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Katie M Campbell, Ann Marie Egloff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Cell|October 18, 2025
CRATER tumor niches facilitate CD8<sup>+</sup> T cell engagement and correspond with immunotherapy successAya Ludin, Georgia L Stirtz, Asaf Tal, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 30

Showing results (271-280 of 293) with videos related to

Sort By:
Pageof 30
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2021
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Katie M Campbell, Ann Marie Egloff, et al.
Cell|July 11, 2025
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanomaEryn Blass, Derin B Keskin, Chloe R Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2020
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Katie M Campbell, Ann Marie Egloff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Cell|October 18, 2025
CRATER tumor niches facilitate CD8<sup>+</sup> T cell engagement and correspond with immunotherapy successAya Ludin, Georgia L Stirtz, Asaf Tal, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 30